Larimar Therapeutics LRMR Stock
$3.20
-3.030300%
Add to favorites
SECTOR
INDUSTRY
COUNTRY
Exchange
Market Cap
$332.43M
LOW - HIGH [24H]
$3.18
-
$3.29
VOLUME [24H]
$1.85M
P/E Ratio
0
Earnings per share
-$2.12
ISIN
US5171251003
Larimar Therapeutics Price Chart
Larimar Therapeutics LRMR Financial and Trading Overview
| Larimar Therapeutics stock price | 3.2 USD |
| Previous Close | 3.48 USD |
| Open | 3.5 USD |
| Bid | 2.58 USD x 200 |
| Ask | 4.44 USD x 200 |
| Day's Range | 3.43 - 3.63 USD |
| 52 Week Range | 2.12 - 6.42 USD |
| Volume | 2.2M USD |
| Avg. Volume | 1.83M USD |
| Market Cap | 364.63M USD |
| Beta (5Y Monthly) | 0.912 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.12 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.11 USD |
LRMR Valuation Measures
| Enterprise Value | 166.65M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.8638566 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 2.3183618 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.968 |
Trading Information
Larimar Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.912 |
| 52-Week Change | 57.82% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 6.42 USD |
| 52 Week Low | 2.12 USD |
| 50-Day Moving Average | 4.3 USD |
| 200-Day Moving Average | 4.02 USD |
LRMR Share Statistics
| Avg. Volume (3 month) | 1.83M USD |
| Avg. Daily Volume (10-Days) | 1.73M USD |
| Shares Outstanding | 103.88M |
| Float | 59.99M |
| Short Ratio | 5.39 |
| % Held by Insiders | 1.09% |
| % Held by Institutions | 85.55% |
| Shares Short | 8.74M |
| Short % of Float | 13.00% |
| Short % of Shares Outstanding | 8.41% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -56.91% |
| Return on Equity (ttm) | -109.82% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -172100000 USD |
| Net Income Avi to Common (ttm) | -166004992 USD |
| Diluted EPS (ttm) | -2.12 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 200.38M USD |
| Total Cash Per Share (mrq) | 1.92 USD |
| Total Debt (mrq) | 3.78M USD |
| Total Debt/Equity (mrq) | 2.39 USD |
| Current Ratio (mrq) | 4.292 |
| Book Value Per Share (mrq) | 1.514 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -131275000 USD |
| Levered Free Cash Flow (ttm) | -71305248 USD |
Profile of Larimar Therapeutics
| Country | United States |
| State | PA |
| City | Bala Cynwyd |
| Address | Three Bala Plaza East |
| ZIP | 19004 |
| Phone | 844 511 9056 |
| Website | https://www.larimartx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 71 |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Q&A For Larimar Therapeutics Stock
What is a current LRMR stock price?
Larimar Therapeutics LRMR stock price today per share is 3.2 USD.
How to purchase Larimar Therapeutics stock?
You can buy LRMR shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Larimar Therapeutics?
The stock symbol or ticker of Larimar Therapeutics is LRMR.
Which industry does the Larimar Therapeutics company belong to?
The Larimar Therapeutics industry is Biotechnology.
How many shares does Larimar Therapeutics have in circulation?
The max supply of Larimar Therapeutics shares is 103.88M.
What is Larimar Therapeutics Price to Earnings Ratio (PE Ratio)?
Larimar Therapeutics PE Ratio is now.
What was Larimar Therapeutics earnings per share over the trailing 12 months (TTM)?
Larimar Therapeutics EPS is -2.12 USD over the trailing 12 months.
Which sector does the Larimar Therapeutics company belong to?
The Larimar Therapeutics sector is Healthcare.
Larimar Therapeutics LRMR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}